Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.73
+0.31 (1.13%)
At close: Dec 5, 2025, 4:00 PM EST
28.00
+0.27 (0.97%)
After-hours: Dec 5, 2025, 7:59 PM EST
Agios Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 8 professional analysts, the 12-month price target for Agios Pharmaceuticals stock ranges from a low of $20 to a high of $48. The average analyst price target of $32.13 forecasts a 15.87% increase in the stock price over the next year.
Price Target: $32.13 (+15.87%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Agios Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jul '25 | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 4 | 4 |
| Buy | 4 | 4 | 4 | 4 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Initiates $38 | Strong Buy | Initiates | $38 | +37.04% | Nov 26, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $32 | Strong Buy | Initiates | $32 | +15.40% | Nov 24, 2025 |
| JP Morgan | JP Morgan | Hold Maintains $37 → $20 | Hold | Maintains | $37 → $20 | -27.88% | Nov 21, 2025 |
| RBC Capital | RBC Capital | Buy → Hold Downgrades $57 → $28 | Buy → Hold | Downgrades | $57 → $28 | +0.97% | Nov 20, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $54 → $32 | Strong Buy | Maintains | $54 → $32 | +15.40% | Nov 20, 2025 |
Financial Forecast
Revenue This Year
46.99M
from 36.50M
Increased by 28.75%
Revenue Next Year
112.52M
from 46.99M
Increased by 139.45%
EPS This Year
-7.20
from 11.64
EPS Next Year
-6.89
from -7.20
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 49.9M | 200.6M | ||||
| Avg | 47.0M | 112.5M | ||||
| Low | 42.1M | 65.7M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | 36.7% | 326.8% | ||||
| Avg | 28.7% | 139.5% | ||||
| Low | 15.5% | 39.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -5.86 | -5.06 | ||||
| Avg | -7.20 | -6.89 | ||||
| Low | -7.21 | -8.20 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.